Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic/Avecor

This article was originally published in The Gray Sheet

Executive Summary

Completion of the $105 mil. Avecor buy March 8 allows creation of a combined Medtronic Perfusion System unit consisting of Avecor and Medtronic's former blood management and cardiopulmonary organization ("The Gray Sheet" Dec. 14, p. 8). Displacement of about 700 positions, including a net reduction of 200, will result primarily from the closure of two newly redundant Medtronic manufacturing facilities. Medtronic plans to phase out production of its Anaheim, California-made Maxima blood oxygenator in favor of Avecor's Affinity, and relocate production of the Medtronic Bio-Pump centrifugal blood pump from Eden Prairie, Minnesota. Medtronic plans an unspecified "one-time transaction-related and restructuring charge" related to the merger during the fourth quarter (ending April 30)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT011473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel